1-3 of 3
Hans-Joerg Buehring, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Fc-Engineered CD133 Antibody for Induction of NK Cell Reactivity Against Cancer Cells

Kathrin Rothfelder, Julia Leibold, Ludger Grosse-Hovest, PhD, Hans-Joerg Buehring, PhD, Gundram Jung, MD, Lothar Kanz, MD, Helmut R Salih, MD
Journal: Blood
Blood (2014) 124 (21): 2739.
https://doi.org/10.1182/blood.V124.21.2739.2739
Published: 2014
Journal Articles

Development and Preclinical Characterization of an Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity Against Myeloid Leukemia

Samuel Koerner, Julia Leibold, Ludger Grosse-Hovest, PhD, Hans-Joerg Buehring, PhD, Gundram Jung, MD, Lothar Kanz, MD, Helmut R. Salih, MD
Journal: Blood
Blood (2014) 124 (21): 2309.
https://doi.org/10.1182/blood.V124.21.2309.2309
Published: 2014
Journal Articles

Elimination Of Minimal Residual Disease (MRD) In AML Patients With a Novel Fc-Optimized FLT3 Antibody (4G8-SDIEM)

Helmut R. Salih, MD, Martin Hofmann, Ludger Grosse-Hovest, PhD, Tina Nuebling, PhD, Maximilian Bamberg, Steffen Aulwurm, PhD, Hans-Joerg Buehring, PHD, Wolfgang A. Bethge, MD, Lothar Kanz, MD, Gundram Jung, MD
Journal: Blood
Blood (2013) 122 (21): 1454.
https://doi.org/10.1182/blood.V122.21.1454.1454
Published: 2013